Panel Deems Drug-Eluting Stents Safe For On-Label Use, But Wants More Data

FDA advisory panel members decided Dec. 7 that the benefit of drug-eluting stent use in FDA-approved indications outweighs the risks. But the panel expressed some skepticism about the strength of data measuring the long-term incidence of blood clots